key: cord-0757541-j596tibi authors: Baldassarre, Lauren A; Yang, Eric H; Cheng, Richard K; DeCara, Jeanne M; Dent, Susan; Liu, Jennifer E; Rudski, Lawrence G; Strom, Jordan B; Thavendiranathan, Paaladinesh; Barac, Ana; Zaha, Vlad G; Bucciarelli-Ducci, Chiara; Ellahham, Samer; Deswal, Anita; Lenneman, Carrie; Villarraga, Hector R; Blaes, Anne H; Ismail-Khan, Roohi; Ky, Bonnie; Leja, Monika J; Scherrer-Crosbie, Marielle title: Cardiovascular care of the oncology patient during COVID-19: An expert consensus document from the ACC Cardio-Oncology and Imaging Councils date: 2020-11-12 journal: J Natl Cancer Inst DOI: 10.1093/jnci/djaa177 sha: 4c19bcaadd1f3c227e26c490e24f1059ce8eb871 doc_id: 757541 cord_uid: j596tibi In response to the coronavirus disease 2019 (COVID-19) pandemic, The Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this expert consensus statement. Cardio-oncology patients–individuals with an active or prior cancer history, and with or at risk of cardiovascular disease–are a rapidly growing population, who are both at increased risk of infection by COVID-19 and experiencing severe and/or lethal complications. Recommendations for optimizing screening and monitoring visits to detect cardiac dysfunction are discussed. In addition, judicious use of multimodality imaging and biomarkers are proposed to identify myocardial, valvular, vascular, pericardial involvement in cancer patients. The difficulties of diagnosing the etiology of cardiovascular complications in patients with cancer and COVID-19 are outlined, along with weighing the advantages against risks of exposure, with the modification of existing cardiovascular treatments and cardiotoxicity surveillance in patients with cancer during the COVID-19 pandemic. In response to the coronavirus disease 2019 (COVID- 19) pandemic, The Cardio-Oncology and Imaging Councils of the American College of Cardiology offers recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients in this expert consensus statement. Cardio-oncology patients--individuals with an active or prior cancer history, and with or at risk of cardiovascular disease--are a rapidly growing population, who are both at in the pandemic and include myocardial injury that can be due to acute coronary syndrome; myocarditis; disseminated intravascular coagulation or cytokine storm; cardiac arrhythmias including malignant arrhythmias; arterial and venous thromboembolism; heart failure, and cardiogenic shock (3) . Recent data also demonstrate subclinical myocardial dysfunction early post recovery from the infection. (4) Cardio-oncology patients (including patients with cancer or a history of cancer, and with or at risk of cardiovascular diseases) are a rapidly growing population, who are both at increased risk of infection by COVID-19 and of experiencing severe and even lethal complications when infected. It is well recognized that immunocompromised individuals, such as patients with cancer or diabetes, are more prone to viral infections (5) . Patients with cancer have reduced physiologic reserve from underlying disease and, in many cases, prior cardiotoxic exposure, resulting in a higher risk for cardiovascular complications (6) . A nationwide analysis from China demonstrated that 1.1% of patients hospitalized with COVID-19 had a history of cancer (7) . A subsequent review of 13 studies (2 in Italy, 11 in China), encompassing close to 5000 patients with symptomatic COVID-19, reported that the pooled prevalence of cancer cases in COVID-19 infected patients was 4.5% (95% confidence interval =3.05% to 5.74%) (8) . In COVID-19 infected patients, the presence of cardiovascular risk factors, established cardiovascular disease (CVD) and cancer have been associated with increased severity of COVID-19 related disease and mortality (7, 9) . In a meta-analysis of six studies including 1527 hospitalized patients, the risk of being in the intensive care unit was 3-fold higher for patients with cardiac or cerebrovascular disease and 2-fold higher for patients with hypertension (10) . The adverse effect of cardiovascular risk factors and cardiac diseases on the prognosis of patients with COVID-19 has been confirmed in studies from Italy (11) and the US (12) . A report of the WHO-China Joint Mission on COVID-19 showed that individuals at highest risk for severe disease and death from COVID-19 included those with CVD or cancer. While patients with no comorbidities had a case-fatality rate (CFR) of 1.4%, rates were much higher for those with hypertension, CVD, or cancer with CFRs of 8.4%, 13.2%, and 7.6%, respectively (13) . More recently, two multicenter studies of more than 800 patients each have been published, emphasizing the association of cancer with increased COVID-19 severity and death (14, 15 Cardio-oncology patients require targeted cardiovascular screening and monitoring, particularly if they are being actively treated with or have had past exposure to potentially cardiotoxic therapies. The COVID-19 pandemic raises specific questions regarding how to conduct screening, surveillance and treatment of this unique population, especially as many patients will need ongoing cancer treatment. Such recommendations must be weighed against the risk of exposure to COVID-19. In this expert consensus document, the Cardio-Oncology and Imaging Councils of the American College of Cardiology offer recommendations to clinicians regarding the cardiovascular care of cardio-oncology patients at the time of the COVID-19 pandemic (Table 1) . Cardio-oncology patients have complex medical issues that require multidisciplinary involvement from their healthcare providers. Given the risks of exposure to both provider and patient with in-person consultation, consideration should be given to the need for and acuity of consultations on an individual basis guided by an ongoing discussion of risks and benefits. Should a consultation be deemed necessary, telehealth and other web-based platforms should be preferentially used if the reason for consultation permits. From the patient perspective, telehealth may streamline the process of meeting with providers from different subspecialties and cardio-oncologists, particularly if they are at different locations, while minimizing potential exposure. For outpatient diagnostic testing, some services, including ambulatory rhythm monitoring to assess for arrhythmias, can be sent to the patient's residence. Additionally, wearable devices used to assess performance status may have utility, as they have been shown to predict clinical outcomes in cancer patients (17) . If a face-to face encounter is necessary, proper personal protective equipment (PPE) should be donned by staff with universal masking of cardio-oncology patients to avoid droplet transmission. Sparing and judicious use of diagnostic testing is recommended to facilitate necessary and time-sensitive treatments that are expected to directly impact patient outcomes. If testing availability permits, cardiooncology patients undergoing elective but necessary procedures and/or hospital admission should be tested for COVID-19 beforehand. Procedures such as cardiac surgery, transcatheter structural valvular interventions, and cardioversion for arrhythmias should be reserved for patients who are symptomatic and/or hemodynamically unstable despite medical therapy. When needed, procedures such as pericardiocentesis should ideally be carried out in a negative pressure setting with staff donning the appropriate PPE. Further published recommendations have been discussed in other society statements (18) (19) (20) . Pandemic During the era of the COVID-19 pandemic, when most oncology patients continue to receive cancer treatment and remain at elevated risk both for cardiotoxic exposure and infection, certain considerations for indicated cardiac imaging studies warrant addressing. Here, we highlight the different cardiac imaging modalities and specific clinical scenarios most applicable to cardio-oncology patients. Given the need to protect patients and service providers from spreading the virus, proposed modifications to the current practice of cardiac screening and monitoring during cancer treatment are discussed. In addition, it is important to be aware of the dynamic changes in the choice of cancer treatment such as prioritization of surgery or neoadjuvant chemotherapy depending on the cancer type and stage, response to treatment, and the patients' individual goals of care. These conditions remain dynamic and such recommendations are subject to change as the COVID-19 crisis evolves. The following summary and recommendations are proposed as a clinical approach to adopt during the pandemic while optimizing cardio-oncology care. Currently published statements from cardiac imaging societies delineate the timing and prioritization of cardiac imaging studies in the general patient population during the COVID-19 pandemic, including recommendations for lab safety and PPE use (18, (21) (22) (23) (24) (25) (26) . However, the urgency and timing of imaging studies specifically in cardio-oncology patients must be carefully considered, especially as cancer treatment must be continued in many patients, as holding these treatments may decrease survival (27) . In both COVID-19 positive and negative oncology patients, the risk versus benefit decision for obtaining cardiac imaging studies for each individual case should be carefully evaluated when considering modifications from standard practice. Additionally, there may be variations in institution protocols and recommendations to decrease exposure, which should be followed. Finally, it is important to be aware of geographic variability of COVID-19 infections, which can impact changes to practice. Our goal is to provide a framework and facilitate optimal use and coordination of cardiac imaging studies to minimize risk and meet cancer treatment needs during the pandemic. Transthoracic echocardiography (TTE) is the mainstay tool in the detection and surveillance of cancer therapy-related cardiac dysfunction (CTRCD) (28, 29) , due to its availability, feasibility and cost-effectiveness. It is also the most affected modality by the pandemic given its high utilization and associated risk of transmission due to close proximity of the performing staff to the patient. Point of care ultrasound (POCUS) allows for a limited cardiac ultrasound at the bedside, and these small devices are easier to disinfect and potentially limit viral transmission. An initial POCUS study can screen and diagnose important cardiovascular findings and help guide need for follow-up focused TTEs. Specifically in cardiooncology patients with known or suspected COVID-19, it can help to distinguish between cardiac and/or pulmonary etiologies of dyspnea which can stem from several potential sources in a cancer patient, including left ventricular (LV) dysfunction from exposure to cardiotoxic therapies, malignant or inflammatory pericardial effusions, heart failure, or other COVID-19related sequelae. POCUS has also been used for assessment of venous thromboembolism (VTE), and given COVID-19 has been associated with an increased risk of thrombosis (30) , oncology patients may be particularly at risk for VTE in the setting of their underlying malignancy, compounded by COVID-19 infection (31) . Transesophageal echocardiography (TEE) is considered an aerosol generating procedure, and it is advisable to reserve TEE for circumstances in which the information obtained is deemed imminently essential to the management of the patient and the information cannot be obtained from other modalities. Due to its high accuracy for left ventricular ejection fraction (LVEF) assessment and ability for assessment of pericardial disease, myocardial inflammation, fibrosis and scar burden, cardiac magnetic resonance (CMR) imaging has a unique role in cardio-oncology (32, 33) . Although the routine use of multi-gated radionuclide angiography (MUGA) in cardio-oncology is declining due to concerns of cumulative radiation exposure, it offers an alternative assessment of LVEF with minimal contact between patients and technicians (34) . Cardiac computed tomography (CCT) has emerging clinical value in cardio-oncology for pre-treatment CVD risk assessment, evaluation of CVD or suspected toxicity during cancer treatment, and in survivors post treatment (35) . CCT may function as an alternate to stress testing to assess CAD in low to intermediate risk patients. Screening and Monitoring of Cardiac Function Before, During, and After Cancer Therapy Early recognition of CTRCD provides an opportunity to mitigate cardiac injury and risk of late cardiac events, which is the centerpiece of cardio-oncology care. Current expert consensusbased surveillance strategies during cardiotoxic therapy are largely guided by treatment related risks and patient specific risk factors (29, 36) . However, the exact frequency and intervals of monitoring varies amongst clinical practice. Baseline imaging for ventricular function prior to treatments is ideal to perform, as the incidence of cardiotoxicity remains elevated in modern clinical trials. The CECCY trial, which comprised of anthracycline chemotherapy, had an incidence of 13.5-14.5% (37) , and Guglin et al showed a 29-32% incidence of cardiotoxicity of patients receiving trastuzumab with and without anthracyclines, all defined as an decline in LVEF (38) . In addition, insurance coverage for cancer treatments may require LVEF assessment prior to initiating treatment. Thus, risks and benefits of widening the frequency and type of cardiotoxicity surveillance should be individually weighed and determined for each patient depending on their risk factor profile, with the imaging and PPE resources available. The following expert consensus for screening and monitoring of cardiac function in patients treated with anthracyclines and/or trastuzumab is summarized in Table 2 . It is acknowledged that current guidelines mostly focus on anthracyclines and HER2 targeted agents but provide limited if any guidance for cardiac monitoring of other anticancer agents. This is mostly due to the limited and short-term cardiovascular data from clinical trials of those other agents. However, it is reasonable to obtain baseline LVEF assessment in those considered to be at high risk for CTRCD, with repeat LVEF assessment during therapy if indicated for cardiac-related symptoms. Patient specific risk factors that are considered high risk are: older age (>60 years), two or more traditional cardiovascular risk factors (smoking, hypertension, diabetes, hyperlipidemia, obesity), prior cardiotoxic cancer therapy or mediastinal irradiation, and compromised cardiac function (LVEF<55%, more than moderate valvular heart disease, or CAD). LV strain assessment can be important in the identification of CTRCD. However, it should only continue to be performed if it does not notably lengthen the acquisition time of the TTE. Monitoring with serial troponin and/or brain natriuretic peptide (BNP) has been proposed to reduce frequency of imaging (39) and promising data has been collected in the research setting (40) . The European Society of Medical Oncology recommends measurements of troponin-I or troponin-T, BNP or N-terminal pro-BNP every 3 to 6 weeks or before each cycle, with 99% upper limit of normal being the threshold (39) . The optimal timing of the blood draw and recommendations on therapeutic decisions based on the results are lacking. However, if serum biomarkers are checked, it is recommended they coincide with patient routine treatment related blood draws, to minimize healthcare setting exposures during the pandemic. Other clinical scenarios are summarized in Table 3 . Cancer patients are at high risk of developing more severe COVID-19 related disease than noncancer patients. However, it is not known if prior exposure to potentially cardiotoxic anti-cancer treatment may modify the cardiac response to COVID-19 infection. Prior to cancer treatment, the decision and timing of when to start should be based on the likelihood that urgent therapy and/or surgery will be disease-modifying. The need to mitigate exposure risk to healthcare workers and other cancer patients must be considered (41) . Additionally, given the concerns of known cardiovascular injury with COVID-19 (7,42-45) Additionally, an elevated troponin or BNP may be nonspecific for acute ischemic/thrombotic pathology if the patient is undergoing active anthracycline and/or anti-HER2 treatments, in which case, this elevation may be a marker of subclinical cardiotoxicity (51) . Other agents, such as certain tyrosine kinase inhibitors (i.e. ponatinib) or fluoropyrimidines (5-fluorouracil based agents) can induce actual ischemic events via thrombotic or vasospastic mechanisms, which may require more invasive diagnostic modalities (52, 53) . COVID-19 infection may, as do other severe viral infections, increase the risk of plaque rupture and the occurrence of acute coronary syndrome (54) . In addition, biomarker elevations with some treatments have been associated with clinically significant declines in cardiac function or worse outcomes, such as proteasome inhibitor cardiotoxicity (i.e. carfilzomib) (55) or cytokine release syndrome during chimeric antigen receptor therapy (56) , which may warrant more intensive monitoring and management. Patients undergoing ICI therapy also may exhibit elevated cardiac biomarkers which may be nonspecific, but may raise the concern of ICI-associated myocarditis (57) . It is important to recognize ICI associated myocarditis early and treat with immunosuppressant medications (i.e. steroids). The difficulty in proceeding with immunosuppressant agents is compounded by the fact that COVID-19 itself can manifest with clinical features of myocarditis(3).Thus, a thorough multidisciplinary evaluation, factoring in duration and timing of prior ICI treatment, signs of cardiac inflammation (e.g. abnormal electrocardiographic (ECG) findings, arrhythmias, abnormal TTE and/or CMR findings) and assessment of other signs of ICI toxicity (58) should be performed (59) . Non-invasive imaging modalities, such as CMR and CCTA, are preferred as the first imaging approach in a patient with suspected ICI-associated myocarditis and possible or confirmed COVID-19 infection. However, if the diagnosis cannot be established, pursuing endomyocardial biopsy should be considered, particularly in patients with hemodynamic instability and if it will change management of the patient. Following cancer treatment, patients may be at increased risk for cardiovascular injury related to direct effects of treatment or immunological effects of therapy. Those with active COVID-19 infection should self-isolate but be more cognizant of signs or symptoms suggesting progressive disease, with a low threshold to seek medical care. There are no data on the effect of COVID-19 on patients with chemotherapy-induced cardiomyopathy, but underlying CVD may be associated with higher risk for adverse outcomes. Risk factors that have been associated with chemotherapy-induced cardiomyopathy such as hypertension, diabetes and CAD have also been associated with worse prognosis with COVID-19 infection (7, (42) (43) (44) (45) . Post-recovery from active COVID-19 infection, cancer patients with either overt or subclinical myocardial injury should undergo repeat cardiac imaging prior to their next treatment cycle. It is reasonable to image recovered cancer patients with risk factors for cardiotoxicity (hypertension, diabetes, CAD). Cardiac biomarkers can be considered and compared with those that may have been drawn during the course of the COVID-19 infection. Registry data of recovered COVID-19 positive patients receiving cancer treatments will allow a better understanding of the short and intermediate risk for cancer therapy related cardiotoxicity. The principles of cardioprotective pharmacologic intervention for the cardio-oncology patient remain unchanged and should be guided by an assessment of an individual patient's risk profile; however, in the COVID-19 era additional complexities have arisen regarding overlapping cardiac medications and COVID-19 infection. Initial concerns were raised about use of angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) in COVID-19 infection (60) . The causative pathogen in COVID-19, the SARS CoV-2 virus(61), binds to the spike protein of angiotensin-converting enzyme 2 (ACE2), a membrane-bound immunopeptidase highly expressed in lung and heart tissue, facilitating viral entry into the respiratory epithelium (62, 63) . As ACE2 levels may be elevated in patients on ACEi and ARBs(62) and a higher risk of adverse complications has been noted in patients with pre-existing CVD (43, 64) , there was initial controversy surrounding continued ACEi and ARB use in COVID-19 infections. Society guidelines recommend against withdrawal of these therapies due to the risk of hypertension and resulting kidney injury that may result (65, 66) . Moreover, the results of 2 meta-analyses, 31 observational studies, and interim results from at least one randomized controlled trial indicate that ACE inhibitors and ARBs are not associated with either the incidence or severity of COVID-19 infection (67, 68) . While there is a signal toward improved outcomes among patients with COVID-19 who continue these medications, the risk versus benefit decision of newly initiating these therapies in the context of COVID-19 is an area of active study. While not stipulated, such guidelines should also apply to angiotensin receptor-neprilysin inhibitors (ARNIs) or other medications containing ACE inhibitors or ARBs. Beta blockers can be considered as first line for cardioprotective therapy in patients treated with cardiotoxic therapy and/or with CTRCD. In individuals with chemotherapy-induced left ventricular dysfunction already prescribed ACE inhibitors or ARBs, these medications may contribute to positive ventricular remodeling (69) and should be continued in the setting of COVID-19 infection. Based on multiple reports (43, 70) , elevated clotting factors such as D-dimer, PT, and fibrinogen have been associated with worsened septic coagulopathy and outcomes in COVID-19 infected patients. Among cancer patients with COVID-19, one study found that 39% have an elevated Ddimer (71) . The International Society of Thrombosis and Haemostasis (ISHT) have put forth guidelines recommending use of low-molecular weight heparin (LMWH) for thromboprophylaxis in all hospitalized patients (including those non-critically ill) with COVID-19 in the absence of contraindications (ie active bleeding or platelet count less than 25 x 10 9 /L) (72) . In one study, individuals with a sepsis-induced coagulopathy score 4 or a D-dimer value > six-fold the upper limit of normal had a lower in-hospital mortality with LWMH prophylaxis (73) . Additionally, LMWH has been shown to have anti-inflammatory properties that may be useful adjunctively in treating COVID infection (74) . Continuation of anticoagulation post hospitalization has also been recommended for consideration in some patients to reduce the risk of thrombosis(75). As with all anticoagulants in cancer patients, the benefits of treatment must be weighed against the risk of hemorrhage on an individual basis and warrants further study (76) . Several agents being investigated in the treatment of COVID-19 (e.g. chloroquine, hydroxychloroquine, lopinavir/ritonavir, and azithromycin) have been implicated in corrected QT (QTc) prolongation and sudden cardiac death; caution is advised in starting these medications and drug-drug interactions should be evaluated (77) . Cardio-oncology patients may be receiving QT prolonging cancer therapy (e.g. arsenic) or medications (e.g. anti-fungals and anti-emetics) at baseline and therefore may be more susceptible to electrolyte disturbances that can cause further QTc prolongation. To reduce the risk of torsade de pointes, QT prolonging COVID-19 medications should not be initiated in patients with a baseline QTc  500 msec or with known congenital long-QT syndrome (77) . Aggressive repletion of electrolytes (i.e. potassium, magnesium) should be performed in all patients. For cardio-oncology patients starting QTc prolonging agents, it is reasonable to monitor their QT interval with more frequent ECGs and withdraw the medication if the QTc exceeds 500 msec (77, 78) . The COVID-19 crisis will resolve geographically at different rates and times, with the entire course of the pandemic likely lasting into 2021. The unprecedented impact the pandemic has had overall on the field of medicine has also affected the practice of cardio-oncology considerably. As there has been widespread cancellation of non-urgent consultations, diagnostic tests, and procedures for numerous indications, cancer patients may be competing for a period of time with other patients with respect to access to technical platforms and human resources. The pandemic has also complicated cardio-oncology education for trainees, a field that has already generated much discussion and debate on an optimal training curriculum needed to achieve competence (79, 80) . From a research standpoint, the suspension of laboratories, research programs, and decreasing clinical volume and revenue may potentially affect programmatic stability; efforts and research funding should be directed to understand the impact of COVID-19 on the cardio-oncology population (81) . This may occur through registries and quality improvement initiatives to evaluate how the pandemic has impacted systems of care both in the cardiac and cancer realms. However, the pandemic has also been a catalyst to increase remote learning and care. From a training standpoint, fellowship programs have made the transition to virtual didactics and meetings (82) ; while a certain element of depersonalization may permeate throughout these interactions, educational resources and lectures (i.e. grand rounds) that were previously institutionally exclusive now have the ability to be viewed anywhere in the world. This can potentially disseminate ideas, education, and research collaborations in a more rapid fashion. Virtual platforms can also be held in a multidisciplinary fashion to discuss cardio-oncology patient care, and trainees overall can be involved in the telehealth aspect of cardio-oncology care. It is possible that telemedicine will play a much more dominant role in outpatient care in the post-COVID-19 era and will be pertinent to the delivery of medical care as a whole. Collaboration between the oncology and cardiology communities will continue to be of upmost importance in taking care of cardio-oncology patients, now even more than ever, during this COVID-19 pandemic. Although this era poses difficulty to the care of these complex patients, it has also challenged practitioners to develop unique and efficient ways to communicate, work together, and approach patient care. Most certainly, the cardio-oncology community will carry these skills into the future and continue to build on this experience to even further strengthen the care of patients in this growing field. , defer c After completion of treatment Defer LVEF assessment c a These recommendations only apply to patients with no prior cardiac dysfunction, those who maintain normal cardiac function during surveillance (LVEF  55%), and those without any cardiac symptoms. Any question of case-specific surveillance for a patient, especially if there is any concern of cardiac disease or symptoms, should prompt a cardio-oncology consultation. Additionally, beyond patient and treatment specific risks, all of these recommendations depend on the time and regional variance of COVID-19 risk. b Recommend medical providers to coordinate LVEF with other appointments to minimize exposure c Duration of deferral is based on time-dependent regional prevalence of COVID-19 pandemic and risk of exposure. d Patient-specific risk factors that are considered high risk for developing cardiac dysfunction include any of the criteria: older age (>60 years), two or more traditional cardiovascular risk factors (smoking, hypertension, diabetes, hyperlipidemia, obesity), prior (87) as well as some cancer therapies (i.e. ibrutinib) (88) . CCTA a to assess left atrial appendage thrombus(89) TEE (typically 1 st line but due to concern for aerosolization CCT can be an option) TTE with agitated saline injection for patent foramen ovale (in setting of stroke) CMR if concern for ventricular thrombus Ischemic heart disease (pre-existing, as many cancer patients with increased risk of CAD(90) vs acquired from cancer therapy (radiation, tyrosine kinase inhibitors including ponatinib) (91), evaluation of chest pain from 5-FU). Routine CAD screening, such as for asymptomatic survivors of childhood cancers and others with radiation exposure can be deferred (92) . CCTA a Functional stress testing (exercise less ideal given concern for aerosolization, pharmacologic preferred via nuclear (PET, SPECT) or Cardiac magnetic resonance) (93) Valvular disease, including endocarditis [valvular disease can be a consequence of radiation and chemotherapy treatment for cancer (94) ] and infective endocarditis can occur in oncology patients and is associated with worse outcomes(95) TTE a TEE (for endocarditis evaluation, consider deferral if transthoracic echocardiogram imaging adequate; can consider if information from transesophageal echocardiogram will imminently change management) CCT (paravalvular abscess assessment) or CMR (structural assessment) Pericardial diseases TTE a CMR a CCT Pulmonary Hypertension, preexisting versus acquired (ie tyrosine kinase inhibitors including dasatinib)(52) Conceptualization; Supervision; Visualization; Writing -original draft Conceptualization; Supervision; Visualization; Writing -original draft MSc (Conceptualization; Visualization; Writing -original draft Writing -original draft Writing -original draft Writing -original draft Sc (Visualization; Writing -original draft Conceptualization; Supervision; Writing -original draft Conceptualization; Supervision; Writing -original draft Writing -original draft Writing -original draft Writing -original draft Writing -original draft Writing -original draft Writing -original draft Writing -original draft Writing -original draft Conceptualization; Supervision; Writing -original draft Conceptualization; Supervision; Visualization; Writing -original draft Writing -review & editing) Visualization; Writing -original draft World Health Organization. Coronavirus disease (COVID-19) pandemic. 2020. 2 Cardiovascular Manifestations and Treatment Considerations in Coronavirus Disease 2019 (COVID-19) Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) Viral Diseases in Transplant and Immunocompromised Patients The Novel Coronavirus Disease (COVID-19) Threat for Patients with Cardiovascular Disease and Cancer Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China Scoping review on the prevalence of cancer in COVID-19 patients Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the Report of the WHO-China Joint Mission on Coronavirus Disease Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study Coronavirus Disease 2019 Case Surveillance-United States Wearable activity monitors to assess performance status and predict clinical outcomes in advanced cancer patients Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC's Interventional Council and SCAI Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology Triage Considerations for Patients Referred for Structural Heart Disease Intervention During the Coronavirus Disease 2019 (COVID-19) Pandemic: An ACC /SCAI Consensus Statement Society for Cardiovascular Magnetic Resonance (SCMR) guidance for the practice of cardiovascular magnetic resonance during the COVID-19 pandemic ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak Guidance and Best Practices for Nuclear Cardiology Laboratories during the Coronavirus Disease 2019 (COVID-19) Pandemic: An Information Statement from ASNC and SNMMI. 2020. 24. Choi AD, Abbara S, Branch KR et al. Society of Cardiovascular Computed Tomography guidance for use of cardiac computed tomography amidst the COVID-19 pandemic Endorsed by the American College of Cardiology ASE Statement on Pointof-Care Ultrasound (POCUS) During the 2019 Novel Coronavirus Pandemic Multimodality Imaging in Evaluation of Cardiovascular complications in Patients with COVID-19 Early Trastuzumab Interruption and Recurrence-Free Survival in ERBB2-Positive Breast Cancer Contemporary Role of Echocardiography for Clinical Decision Making in Patients During and After Cancer Therapy Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study Cardiovascular Magnetic Resonance in the Oncology Patient The Role of Cardiac Magnetic Resonance Imaging to Detect Cardiac Toxicity From Cancer Therapeutics Nuclear cardiology in the context of multimodality imaging to detect cardiac toxicity from cancer therapeutics: Established and emerging methods Applications of Cardiac Computed Tomography in the Cardio-Oncology Population Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial Randomized Trial of Lisinopril Versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients With Breast Cancer Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations Biomarkers in cancer therapy related cardiac dysfunction (CTRCD) A War on Two Fronts: Cancer Care in the Time of COVID-19 Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19 Patient Care Information Inflammation: a common contributor to cancer, aging, and cardiovascular diseases-expanding the concept of cardio-oncology Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents COVID-19) and Cardiovascular Disease The Role of Biomarkers in Detection of Cardio-toxicity Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction Cardio-Oncology: Vascular and Metabolic Perspectives: A Scientific Statement From the American Heart Association Vascular Toxicities of Cancer Therapies: The Old and the New-An Evolving Avenue Influenza infection and risk of acute myocardial infarction in England and Wales: a CALIBER self-controlled case series study Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T) Myocarditis in Patients Treated With Immune Checkpoint Inhibitors Association between Myocarditis and other Immune-Related Adverse Events secondary to Immune Checkpoint Inhibitor Use Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin COVID-19 and Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: What Is the Evidence A pneumonia outbreak associated with a new coronavirus of probable bat origin COVID-19 and the cardiovascular system ACE2: from vasopeptidase to SARS virus receptor Clinical Characteristics of 138 Hospitalized Patients With Novel Coronavirus-Infected Pneumonia in Wuhan, China European Society of Cardiology. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers American College of Cardiology. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19 Update Alert 3: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults: A Living Systematic Review Prevention of high-dose chemotherapyinduced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia ISTH interim guidance on recognition and management of coagulopathy in COVID-19: A Comment New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: a retrospective analysis of a nationwide survey More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Anticoagulation Strategies in Patients With Cancer: JACC Review Topic of the Week Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment American College of Cardiology Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment for COVID-19 Preparing the Cardiovascular Workforce to Care for Oncology Patients: JACC Review Topic of the Week Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty COVID-19 Clinical Trials: A Primer for the Cardiovascular and Cardio-Oncology Communities Adapting the Educational Environment for Cardiovascular Fellows-in-Training During the COVID-19 Pandemic COVID-19: Myocardial injury in survivors Cardiovascular magnetic resonance in myocarditis: A JACC White Paper Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology Cancer increases the risk of atrial fibrillation during long-term follow-up (OPERA study) High incidence of atrial fibrillation in patients treated with ibrutinib Multimodality imaging of left atrium in patients with atrial fibrillation Risk of coronary heart disease in patients with cancer: a nationwide follow-up study from Sweden Precision Cardio-Oncology Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography Cardiovascular magnetic resonance and single-photon emission computed tomography for diagnosis of coronary heart disease (CE-MARC): a prospective trial Valvular Heart Disease in Cancer Patients: Etiology, Diagnosis, and Management Infective Endocarditis in Cancer Patients-Causative Organisms, Predisposing Procedures, and Prognosis Differ From Infective Endocarditis in Non-Cancer Patients cardiotoxic cancer therapy or mediastinal irradiation, compromised cardiac function (LVEF<55%, more than moderate valvular heart disease, or CAD) e Patients are considered non-high risk if they do not meet any of the following criteria: older age (>60 years), two or more traditional cardiovascular risk factors (smoking, hypertension, diabetes, hyperlipidemia, obesity), prior cardiotoxic cancer therapy or mediastinal irradiation, compromised cardiac function (LVEF<55%, more than moderate valvular heart disease No new data were generated or analysed in support of this research.